• PTC Therapeutics said it cannot resolve differences it has with the FDA in interpreting clinical trial data for Translarna, a drug it developed for Duchenne muscular dystrophy. • The rare disease drug developer’s decision to withdraw Translarna’s FDA submission comes nearly a year after a negative European regulatory decision for the drug. • The post PTC Therapeutics Ends Bid to Seek FDA Approval for Rare Muscle Disease Drug appeared first on MedCity News .

Article Summaries:

  • PTC Therapeutics has withdrawn its FDA submission for Translarna, a drug it developed for Duchenne muscular dystrophy, citing unresolved differences with the agency over the interpretation of clinical‑trial data. The decision follows a nearly year‑long effort to secure approval and comes after a negative regulatory outcome in Europe. PTC stated it could not reconcile the FDA’s concerns with its own analysis of the trial results, effectively ending its bid for U.S. approval of the rare‑disease therapy. The move underscores the challenges of aligning regulatory expectations with clinical evidence for novel treatments.

Sources: